ID

13060

Beschrijving

Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00083577

Link

https://clinicaltrials.gov/show/NCT00083577

Trefwoorden

  1. 13-01-16 13-01-16 -
Houder van rechten

CC BY-NC 3.0

Geüploaded op

13 januari 2016

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Multiple Myeloma NCT00083577

Eligibility Multiple Myeloma NCT00083577

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
all patients must have a confirmed diagnosis of previously treated, active multiple myeloma
Beschrijving

multiple myeloma

Datatype

boolean

Alias
UMLS CUI [1]
C0026764
myeloma protein should be evident from which to evaluate response
Beschrijving

myeloma protein

Datatype

boolean

Alias
UMLS CUI [1]
C0027015
must be 18 years of age or older. women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
Beschrijving

age, contraception

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0700589
patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
Beschrijving

informed consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
patients must have a total white blood cell count of 2,000 k/microliters. patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
Beschrijving

white blood cell count

Datatype

boolean

Alias
UMLS CUI [1]
C0023508
patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dl.
Beschrijving

liver function

Datatype

boolean

Alias
UMLS CUI [1]
C1278039
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients must not have an active infection requiring parenteral antibiotics
Beschrijving

active infection

Datatype

boolean

Alias
UMLS CUI [1]
C0009450
no other concurrent therapy for myeloma is permitted while on thalidomide
Beschrijving

concurrent therapy

Datatype

boolean

Alias
UMLS CUI [1]
C0039736

Similar models

Eligibility Multiple Myeloma NCT00083577

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
multiple myeloma
Item
all patients must have a confirmed diagnosis of previously treated, active multiple myeloma
boolean
C0026764 (UMLS CUI [1])
myeloma protein
Item
myeloma protein should be evident from which to evaluate response
boolean
C0027015 (UMLS CUI [1])
age, contraception
Item
must be 18 years of age or older. women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
boolean
C0001779 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
informed consent
Item
patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
boolean
C0021430 (UMLS CUI [1])
white blood cell count
Item
patients must have a total white blood cell count of 2,000 k/microliters. patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
boolean
C0023508 (UMLS CUI [1])
liver function
Item
patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dl.
boolean
C1278039 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
active infection
Item
patients must not have an active infection requiring parenteral antibiotics
boolean
C0009450 (UMLS CUI [1])
concurrent therapy
Item
no other concurrent therapy for myeloma is permitted while on thalidomide
boolean
C0039736 (UMLS CUI [1])

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial